March 12, 2025
Ono Pharmaceutical Acquires Global Rights to Ionis’ Sapablursen for Polycythemia Vera in $940M Deal
Ono Pharmaceutical, Ionis Pharmaceuticals, sapablursen, polycythemia vera, licensing agreement, RNA-targeted medicine
Pharmaceutical Giants Mallinckrodt and Endo Explore $7 Billion Merger
Pharmaceutical merger, Mallinckrodt, Endo, $7 billion deal, Specialty pharmaceutical companies, Post-bankruptcy consolidation, Opioid crisis fallout
Gilead Faces Legal Challenges Over Alleged HIV Drug Patent Extension Strategy
Product hopping, Patent extension, HIV drugs, Tenofovir, Antitrust, Truvada, TAF vs TDF
Viking Therapeutics Signs $150 Million Manufacturing Deal with CordenPharma for Obesity Drug VK2735
Viking Therapeutics, CordenPharma, VK2735, Obesity drug, GLP-1/GIP dual agonist, Contract manufacturing, API production, Fill/finish capacity, Subcutaneous and oral formulations
FDA’s medical review departments remain largely untouched (for now) by Musk-led cuts
FDA, medical review, drug approval, device regulation, staff cuts, Elon Musk, DOGE, government efficiency
Merck opens $1B Gardasil manufacturing facility in North Carolina
Merck, Facility (object), Manufacture, Durham, North Carolina
Daiichi turns to Nosis for AI-designed RNA delivery tech
Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease
Harbour BioMed Launches Élancé Therapeutics to Develop Next-Generation Obesity Treatments
Harbour BioMed, Élancé Therapeutics, Obesity therapies, Bispecific antibody technology, Next-generation treatments
Mixed pivotal data for Pfizer, Arvinas’ protein degrader in breast cancer
Pfizer, Vepdegestrant, Clinical Trials, ESR1 gene, Statistical Significance, Improvement, Progression-Free Survival, Market
Merck Opens $1 Billion Vaccine Manufacturing Facility in North Carolina
Merck, vaccine manufacturing, Durham, North Carolina, Gardasil, HPV vaccine, pharmaceutical industry, US manufacturing